Advantex Marketing I (ATXMF) 0.0010 $ATXMF Advantex

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advantex Marketing I (ATXMF) 0.0010 $ATXMF

Advantex Announces Fiscal 2016 Third Quarter Results
Marketwire Canada - Mon May 30, 4:53PM CDT
EBITDA (1) of $1.1 million after restructuring of Fiscal year 2015

Advantex Announces Extension of Its Agreement With CIBC
Marketwired - Thu Apr 14, 1:32PM CDT
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty-reward programs, today announced that it has agreed with Canadian Imperial Bank of Commerce ("CIBC" on an extension until December 31, 2016 of their agreement which was due to expire on September 30, 2016.

Advantex Announces Fiscal 2016 First Quarter Results
Marketwired - Thu Nov 26, 3:42PM CST
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty-reward programs, announced its results for the three months ended September 30, 2015.

Advantex Updates Business Prospects and Announces Fiscal 2015 Results
Marketwired - Wed Oct 28, 4:18PM CDT
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty- reward programs, announced its results for Fiscal year ended June 30, 2015.

Advantex Renews $8.5m Credit Facility
Marketwired - Wed Oct 07, 5:57PM CDT
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty-reward programs, has renewed its credit facility with Accord Financial Inc. for one year to December 2016.

Advantex Reports Financial Results for the Third Quarter of Fiscal 2015
Marketwire Canada - Fri May 29, 4:15PM CDT
Advantex Marketing International Inc. (CSE:ADX), a specialist in loyalty marketing programs, today reported a net loss of $2,582,155 for the three months ended March 31, 2015, compared with net loss of $396,066 for the same period a year earlier.

Advantex Reports Financial Results for the Second Quarter of Fiscal 2015
Marketwired - Mon Mar 02, 3:06PM CST
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty-reward programs, today reported a net loss of $144,079 for the three months ended December 31, 2014, compared with net income of $74,983 for the same period a year earlier.

Advantex Adapts to New Economic Realities
Marketwired - Wed Jan 28, 3:05PM CST
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty-reward programs, is taking a number of pre-emptive measures in response to recent developments in the Canadian marketplace.

Advantex Returns to Profitability in First Quarter of Fiscal 2015
Marketwired - Fri Nov 21, 7:31AM CST
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty-reward programs, today reported net income of $19,807 for the three months ended September 30, 2014.

Advantex and Aimia Renew Aeroplan Partnership
Marketwired - Fri Nov 07, 10:58AM CST
Advantex Marketing International Inc. (CSE: ADX), a specialist in marketing loyalty-reward programs, and Aimia Canada Inc., a global leader in loyalty management and owner of the Aeroplan program, announced today the renewal of a multi-year agreement.

Advantex Announces Update on Its Partnership With Aeroplan
Marketwired - Fri Oct 31, 5:15PM CDT
Advantex Marketing International Inc. ("Advantex" (CSE: ADX), a leading specialist in the marketing services industry, announced today that it has agreed with Aimia Canada Inc. ("Aeroplan" to further extend to November 30th, 2014 the extension, due to expire on October 31, 2014, to their existing agreement.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading